Document Detail


Combined radiation therapy and cisplatin for locally advanced carcinoma of the urinary bladder.
MedLine Citation:
PMID:  8374879     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: This study evaluates feasibility and results of combined treatment of cisplatin and radiation therapy for patients with inoperable invasive bladder carcinoma. METHODS: From January 1988 to October 1991, 69 patients received radiation therapy and concomitant cisplatin. Median age was 71 years. Most tumors were locally advanced and high grade. A macroscopically complete transurethral resection was performed initially in 18 patients. Dose of pelvic radiation ranged from 40 Gy to 45 Gy, and total dose to the bladder ranged from 55 Gy to 60 Gy. Concomitant continuous cisplatin infusion at a dose of 20-25 mg/m2/day for 5 days was delivered during the 2nd and 5th weeks of radiation. RESULTS: As of April 1993, the median follow-up time was 36.4 months (range, 18-70 months). Ninety-one percent of the patients completed radiation therapy as planned, and 78.3% completed two courses of chemotherapy. Despite one treatment-related death due to renal failure, toxicity was generally mild and acceptable. Sixty-three patients were evaluable for response. Forty-eight patients (76.2%) achieved a complete response. Actuarial overall 3-year survival rate was 37.1% for all patients. Among the patients who experienced complete response, the 3-year actuarial local control and disease-free survival rates were 65.4% and 56.3%, respectively. Twenty-six patients (37.7%) are alive and disease-free with bladder preservation. One patient is alive and disease-free after salvage cystectomy. CONCLUSIONS: Concomitant cisplatin and radiation therapy offers high probability of complete response and local control in patients with invasive bladder cancer unsuitable for surgery. These results provide a basis for randomized studies comparing this approach with conventional therapy for patients with operable carcinoma.
Authors:
B Chauvet; Y Brewer; C F?lix-Faure; J L Davin; P Vincent; F Reboul
Related Documents :
8694539 - Tpa prognostic value in superficial bladder cancer.
17270649 - Urothelial carcinoma recurrence in ileal orthotopic neobladder: urethrectomy and creati...
17499279 - Urachal carcinoma: contemporary surgical outcomes.
2712609 - Quality of life in patients with advanced bladder cancer treated by tumorectomy and sys...
8460449 - Cell and tumor markers' immunohistochemistry in transitional cell carcinoma of the blad...
9073049 - Survival after curative treatment of muscle-invasive bladder cancer.
18094659 - Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with ra...
21507649 - A retrospective survey of patients with malignant gliomas treated in the neuro-oncologi...
24023339 - Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with pe...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Cancer     Volume:  72     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  1993 Oct 
Date Detail:
Created Date:  1993-10-20     Completed Date:  1993-10-20     Revised Date:  2010-03-24    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2213-8     Citation Subset:  AIM; IM    
Affiliation:
Unit? de Traitement des Cancers Urologiques, Clinique Sainte Catherine, Avignon, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Cisplatin / administration & dosage
Combined Modality Therapy
Female
Humans
Male
Middle Aged
Radiotherapy Dosage
Survival Rate
Treatment Outcome
Urinary Bladder Neoplasms / therapy*
Chemical
Reg. No./Substance:
15663-27-1/Cisplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Localized renal cell carcinoma treated by radical nephrectomy. Influence of pathologic data and the ...
Next Document:  Extraskeletal mesenchymal chondrosarcoma of the orbit.